The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015–2024)

Background/Objectives: Academic sponsored cancer clinical trials (ACCTs) are essential for advancing patient-centered care, particularly in areas underserved by commercial re-search. In Canada, the Canadian Cancer Clinical Trials Network (3CTN) was established to support high-quality multi-centre ACCTs. This study evaluates the outcomes and im-pact of trials supported by 3CTN between 2015 and 2024. Methods: We conducted a descriptive analysis of 350 ACCTs that were closed to recruitment and had primary completion dates within the study period. Trial characteristics, results, publication rates, and in-corporation into clinical guidelines were assessed using registry data, peer-reviewed publications, and structured searches of oncology guidelines. Results: Among the 350 complete trials, 116 were Phase III studies. Of these, 36% were incorporated into clinical practice guidelines and 7% were likely to be incorporated. Overall, 81% of trials were published in journals, and 45% posted results in public registries. Trials addressed diverse cancer types, with notable contributions in rare cancers and vulnerable populations. Conclusions: 3CTN supported ACCTs had high completion and reporting rates, with substantial influence on clinical practice. These findings highlight the importance of sustained infrastructure and funding ACCTs and their role in improving cancer care. The impact achieved with relatively modest investment from public funders underscores the value of sustained investment in investigator-led research and coordinated network support.